In total, 25 patients (67.8%) who received combination therapy had at least one treatment-related AE, including abdominal pain (n = 5), increased alanine aminotransferase/aspartate aminotransferase (n = 5), fever (n = 4), hypertension (n = 3), lymphopenia (n = 2), hand-foot skin reactions (n = 2), decreased appetite (n = 2), nausea/vomiting (n = 2), reactive cutaneous capillary endothelial proliferation (RCCEP, n = 1), diarrhea (n = 1), fatigue (n = 1), leukopenia (n = 1), neutropenia (n = 1), and anemia (n = 1). This evidence concerns the gene GPT and lymphopenia.